Wipfli Financial Advisors LLC Invests $26,000 in 10x Genomics, Inc. (NASDAQ:TXG)

Wipfli Financial Advisors LLC purchased a new position in 10x Genomics, Inc. (NASDAQ:TXGGet Rating) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 929 shares of the company’s stock, valued at approximately $26,000.

A number of other hedge funds have also made changes to their positions in TXG. Raymond James & Associates lifted its position in shares of 10x Genomics by 19.3% in the first quarter. Raymond James & Associates now owns 53,009 shares of the company’s stock worth $4,032,000 after purchasing an additional 8,570 shares in the last quarter. US Bancorp DE lifted its position in shares of 10x Genomics by 39.6% in the first quarter. US Bancorp DE now owns 9,711 shares of the company’s stock worth $739,000 after purchasing an additional 2,753 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of 10x Genomics by 617.9% in the first quarter. PNC Financial Services Group Inc. now owns 2,046 shares of the company’s stock worth $155,000 after purchasing an additional 1,761 shares in the last quarter. MetLife Investment Management LLC purchased a new stake in shares of 10x Genomics in the first quarter worth approximately $416,000. Finally, BlackRock Inc. lifted its position in shares of 10x Genomics by 14.2% in the first quarter. BlackRock Inc. now owns 9,156,992 shares of the company’s stock worth $696,572,000 after purchasing an additional 1,138,358 shares in the last quarter. 74.34% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Morgan Stanley cut their price objective on shares of 10x Genomics from $70.00 to $64.00 and set an “overweight” rating on the stock in a research report on Friday, November 4th. JPMorgan Chase & Co. cut their price objective on shares of 10x Genomics from $65.00 to $55.00 in a research report on Thursday, November 3rd. The Goldman Sachs Group cut their price objective on shares of 10x Genomics from $35.00 to $25.00 and set a “sell” rating on the stock in a research report on Thursday, October 13th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of 10x Genomics in a research report on Tuesday, December 13th. They set a “buy” rating and a $50.00 price objective on the stock. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $51.00.

Insider Transactions at 10x Genomics

In other news, CFO Justin J. Mcanear sold 1,626 shares of the firm’s stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $34.07, for a total value of $55,397.82. Following the sale, the chief financial officer now owns 76,764 shares in the company, valued at $2,615,349.48. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other 10x Genomics news, CFO Justin J. Mcanear sold 1,626 shares of 10x Genomics stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $34.07, for a total transaction of $55,397.82. Following the sale, the chief financial officer now owns 76,764 shares in the company, valued at $2,615,349.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 2,361 shares of 10x Genomics stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $34.07, for a total transaction of $80,439.27. Following the sale, the insider now owns 217,713 shares in the company, valued at approximately $7,417,481.91. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 6,663 shares of company stock worth $227,008. Insiders own 11.08% of the company’s stock.

10x Genomics Stock Up 5.2 %

Shares of TXG stock opened at $47.33 on Friday. 10x Genomics, Inc. has a 12 month low of $23.81 and a 12 month high of $100.00. The business’s 50 day moving average is $37.44 and its two-hundred day moving average is $35.89. The company has a market cap of $5.42 billion, a PE ratio of -31.86 and a beta of 1.67.

10x Genomics (NASDAQ:TXGGet Rating) last announced its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.08. 10x Genomics had a negative return on equity of 21.01% and a negative net margin of 33.20%. The company had revenue of $131.10 million for the quarter, compared to the consensus estimate of $129.13 million. During the same quarter last year, the company posted ($0.15) earnings per share. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. As a group, equities analysts expect that 10x Genomics, Inc. will post -1.6 EPS for the current fiscal year.

About 10x Genomics

(Get Rating)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Featured Articles

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXGGet Rating).

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.